Total number of voting rights and share capital in Novo Nordisk A/S
as of 30 June 2008.
In accordance with Section 6 of the Danish Statutory Order on Issuers
Disclosure Obligations, Novo Nordisk is required to publish the total
number of voting rights and the size of the share capital in Novo
Nordisk as per the end of the month where changes have occurred.
Referring to Stock Exchange Announcement no 35/2008 dated 13 June
2008, please find below a statement regarding the total number of
voting rights and share capital in Novo Nordisk as per 30 June 2008.
+---------------------------------------------------------------+
| | Number of shares | Nominal value | Number of votes |
| | (nominal value | (DKK) | |
| | DKK 1) | | |
|----------+------------------+---------------+-----------------|
| A shares | | | |
| | 107,487,200 | 107,487,200 | 107,487,200,000 |
|----------+------------------+---------------+-----------------|
| B shares | | | |
| | 526,512,800 | 526,512,800 | 52,651,280,000 |
+---------------------------------------------------------------+
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 40 / 2008